Skip to content

Study · Non-randomized trial · n = 11 · 2009

5 results

High doses of GnRH antagonists are efficient in the management of severe ovarian hyperstimulation syndrome.

Bonilla-Musoles FM, Raga F, Castillo JC, Sanz M, Dolz M, Osborne N

Clinical and experimental obstetrics & gynecology1 Jan 2009Cited by 9 (Europe PMC)

PMID19688946 (opens in a new tab)PepBankPUB-19688946
Publisher pageAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with severe early-onset OHSS, peritoneal fluid regressed faster with cetrorelix than support therapy alone.

    In plain wordsIn patients with severe ovarian hyperstimulation, abdominal fluid decreased faster with cetrorelix than support therapy alone.

    Peptide
    Cetrorelix
    Outcome
    IncreasePeritoneal fluid regression
    Study

    n = 11

    Comparator
    Support therapy alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.0 mgAs given in this study (human).

    Source sentences

    Summary
    Peritoneal fluid regression measured by ultrasound was faster on the study group compared with controls.
    2 context sentences
    Summary · context
    Six infertile patients who had been scheduled for embryo transfer and developed early-onset severe OHSS with ascites and hemoconcentration were chosen for treatment with 3.0 mg of a GnRH antagonist (Cetrotide; Cetrorelix, Serono, Madrid, Spain).
    Summary · context
    The response of these patients was compared with five patients with severe early-onset OHSS who received support therapy alone.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with severe early-onset OHSS, hematocrit remained comparable between cetrorelix and support therapy alone.

    In plain wordsIn patients with severe ovarian hyperstimulation, hematocrit remained similar with cetrorelix and support therapy alone.

    Peptide
    Cetrorelix
    Outcome
    No significant changeHematocrit
    Study

    n = 11

    Comparator
    Support therapy alone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.0 mgAs given in this study (human).

    Source sentences

    Summary
    Hematocrit remained comparable in both groups during follow-up.
    2 context sentences
    Summary · context
    Six infertile patients who had been scheduled for embryo transfer and developed early-onset severe OHSS with ascites and hemoconcentration were chosen for treatment with 3.0 mg of a GnRH antagonist (Cetrotide; Cetrorelix, Serono, Madrid, Spain).
    Summary · context
    The response of these patients was compared with five patients with severe early-onset OHSS who received support therapy alone.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with severe early-onset OHSS, estradiol dropped significantly a few days after cetrorelix treatment.

    In plain wordsIn patients with severe ovarian hyperstimulation, estradiol fell significantly a few days after cetrorelix treatment.

    Peptide
    Cetrorelix
    Outcome
    DecreaseEstradiol
    Study

    n = 6

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.0 mgAs given in this study (human).

    Source sentences

    Summary
    Estradiol (E2) levels dropped significantly a few days after treatment.
    2 context sentences
    Summary · context
    Six infertile patients who had been scheduled for embryo transfer and developed early-onset severe OHSS with ascites and hemoconcentration were chosen for treatment with 3.0 mg of a GnRH antagonist (Cetrotide; Cetrorelix, Serono, Madrid, Spain).
    Summary · context
    The response of these patients was compared with five patients with severe early-onset OHSS who received support therapy alone.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with severe early-onset OHSS, two cases required a second cetrorelix bolus during four days of observation.

    In plain wordsIn patients with severe ovarian hyperstimulation, two cases required a second cetrorelix dose during four days of observation.

    Peptide
    Cetrorelix
    Outcome
    Not applicableSecond bolus requirement
    Study

    n = 6

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.0 mgAs given in this study (human).

    Measurements

    Cases needing a second bolus
    2 cases
    cetrorelix-treated patients

    Source sentences

    Summary
    In two cases a second bolus of GnRH-antagonist was used due to clinical and biochemical findings during the four days of observation following the initial dose.
    2 context sentences
    Summary · context
    Six infertile patients who had been scheduled for embryo transfer and developed early-onset severe OHSS with ascites and hemoconcentration were chosen for treatment with 3.0 mg of a GnRH antagonist (Cetrotide; Cetrorelix, Serono, Madrid, Spain).
    Summary · context
    The response of these patients was compared with five patients with severe early-onset OHSS who received support therapy alone.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with severe early-onset OHSS, none treated with cetrorelix required paracentesis.

    In plain wordsIn patients with severe ovarian hyperstimulation, none treated with cetrorelix required abdominal fluid drainage.

    Peptide
    Cetrorelix
    Outcome
    Not applicableParacentesis requirement
    Study

    n = 6

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3.0 mgAs given in this study (human).

    Source sentences

    Summary
    None of the patients treated with GnRH antagonists required paracentesis.
    2 context sentences
    Summary · context
    Six infertile patients who had been scheduled for embryo transfer and developed early-onset severe OHSS with ascites and hemoconcentration were chosen for treatment with 3.0 mg of a GnRH antagonist (Cetrotide; Cetrorelix, Serono, Madrid, Spain).
    Summary · context
    The response of these patients was compared with five patients with severe early-onset OHSS who received support therapy alone.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.